Wall Street analysts expect that AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will announce $129.43 million in sales for the current quarter, according to Zacks. Seven analysts have provided estimates for AMAG Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $116.82 million and the highest estimate coming in at $153.24 million. AMAG Pharmaceuticals posted sales of $153.74 million during the same quarter last year, which suggests a negative year-over-year growth rate of 15.8%. The firm is expected to report its next quarterly earnings results on Thursday, November 1st.
On average, analysts expect that AMAG Pharmaceuticals will report full year sales of $524.93 million for the current fiscal year, with estimates ranging from $487.62 million to $547.44 million. For the next fiscal year, analysts expect that the company will post sales of $423.85 million, with estimates ranging from $384.14 million to $476.11 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow AMAG Pharmaceuticals.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.75) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.54). AMAG Pharmaceuticals had a negative return on equity of 2.77% and a negative net margin of 36.87%. The firm had revenue of $146.25 million during the quarter, compared to the consensus estimate of $156.26 million. During the same period in the previous year, the company posted ($0.40) EPS. The firm’s revenue for the quarter was up 12.2% compared to the same quarter last year.
Shares of AMAG traded up $0.90 during trading hours on Thursday, hitting $21.45. The stock had a trading volume of 665,700 shares, compared to its average volume of 867,235. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.95 and a current ratio of 2.06. AMAG Pharmaceuticals has a 52 week low of $11.93 and a 52 week high of $26.10. The firm has a market cap of $711.86 million, a price-to-earnings ratio of -3.76 and a beta of 0.48.
In related news, CEO William K. Heiden sold 5,000 shares of the company’s stock in a transaction dated Tuesday, August 7th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the chief executive officer now owns 328,015 shares in the company, valued at approximately $8,200,375. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 4.00% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of AMAG. Swiss National Bank lifted its position in AMAG Pharmaceuticals by 13.0% during the 1st quarter. Swiss National Bank now owns 63,457 shares of the specialty pharmaceutical company’s stock worth $1,279,000 after buying an additional 7,300 shares in the last quarter. Northern Trust Corp lifted its position in AMAG Pharmaceuticals by 1.0% during the 1st quarter. Northern Trust Corp now owns 458,445 shares of the specialty pharmaceutical company’s stock worth $9,237,000 after buying an additional 4,468 shares in the last quarter. Employees Retirement System of Texas lifted its position in AMAG Pharmaceuticals by 37.5% during the 1st quarter. Employees Retirement System of Texas now owns 66,000 shares of the specialty pharmaceutical company’s stock worth $1,330,000 after buying an additional 18,000 shares in the last quarter. California Public Employees Retirement System lifted its position in AMAG Pharmaceuticals by 14.4% during the 1st quarter. California Public Employees Retirement System now owns 96,339 shares of the specialty pharmaceutical company’s stock worth $1,941,000 after buying an additional 12,098 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in AMAG Pharmaceuticals by 94.9% during the 1st quarter. PNC Financial Services Group Inc. now owns 25,652 shares of the specialty pharmaceutical company’s stock worth $518,000 after buying an additional 12,491 shares in the last quarter.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Read More: How Do I Invest in Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.